Mansoureh Barzegar

Dr. Mansoureh Barzegar

LSUHSC-Shreveport
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2022 in Life Sciences
Verified
Journal Article
Closed access
SDShaghayegh Doudi
Shaghayegh Doudi
MBMansoureh Barzegar
Mansoureh Barzegar
ETElham Angouraj Taghavi
Elham Angouraj Taghavi
MEMohammad Reza Eini
Mohammad Reza Eini
AEArian Ehterami
Arian Ehterami
NMNaimeh Mahheidari
Naimeh Mahheidari

22 June 2021 in Stem Cells
Verified
Journal Article
Open access
PDF file
MBMansoureh Barzegar
Mansoureh Barzegar
SVShantel Vital
Shantel Vital
KSKaren Y. Stokes
Karen Y. Stokes
YWYuping Wang
Yuping Wang
JYJ. Winny Yun
J. Winny Yun
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander
Thromboembolic stroke remains a major cause of neurological disability and death. Current stroke treatments (aspirin, tissue plasminogen activator) are significantly limited by timing and risks for hemorrhage which have driven researchers to explore other approaches. Stem cell-based therapy appears to be an effective option for ischemic stroke. Besides trans-differentiation into neural cells, stem cells also provide acute protection via paracrine signaling pathways through which releasing neuroprotective factors. We previously reported that intraperitoneal administration of human placenta mesenchymal stem cell (hPMSC) therapy upon reperfusion significantly protected the brain against middle cerebral artery occlusion (MCAO)-induced injury. In the present study, we specifically investigated the role of hPMSC-derived angiotensin converting enzyme-2 (ACE-2) in protection of MCAO-induced brain injury by measurement of brain tissue viability, cerebral blood flow, and neurological score. Here, we report for the first time that hPMSC expressing substantial amount of ACE-2, which mediates hPMSC protection in the MCAO model. Strikingly, we found that the protective effects of hPMSC in MCAO-induced brain injury could be attenuated by pretreatment of hPMSCs with MLN-4760, a specific inhibitor of ACE-2 activity, or by transfection of hPMSCs with ACE-2-shRNA-lentivirus. The hPMSC-derived ACE-2 specific protective mechanism was further demonstrated by administration of PD123319, an Angiotensin type-2 receptor antagonist, or A779, a MasR antagonist. Importantly, our study demonstrated that the protective effects of hPMSC in experimental stroke are ACE-2/MasR dependent and this signaling pathway represents an innovative and highly promising approach for targeted stroke therapy.

11 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MBMansoureh Barzegar
Mansoureh Barzegar
KSKaren Y. Stokes
Karen Y. Stokes
OCOleg Y Chernyshev
Oleg Y Chernyshev
RKRoger Everett Kelley
Roger Everett Kelley
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander
Ischemic stroke remains the leading cause of neurologically based morbidity and mortality. Current stroke treatment is limited to two classes of FDA-approved drugs: thrombolytic agents (tissue plasminogen activator (tPA)) and antithrombotic agents (aspirin and heparin), which have a narrow time-window (<4.5 h) for administration after onset of stroke symptoms. While thrombolytic agents restore perfusion, they carry serious risks for hemorrhage, and do not influence damage responses during reperfusion. Consequently, stroke therapies that can suppress deleterious effects of ischemic injury are desperately needed. Angiotensin converting enzyme-2 (ACE2) has been recently suggested to beneficially influence experimental stroke outcomes by converting the vasoconstrictor Ang II into the vasodilator Ang 1–7. In this review, we extensively discuss the protective functions of ACE2-Ang (1–7)-MasR axis of renin angiotensin system (RAS) in ischemic stroke.

27 July 2026 in Cells
Verified
Journal Article
Open access
PDF file
MBMansoureh Barzegar
Mansoureh Barzegar
ADAsmita Dhukhwa
Asmita Dhukhwa
VPVaidehi Nilesh Patel
Vaidehi Nilesh Patel
FVFernanda Elisabeth Carrizo Velasquez
Fernanda Elisabeth Carrizo Velasquez
SDSamirjit Das
Samirjit Das
XCXitiz Chamling
Xitiz Chamling
MicroRNAs (miRNAs) are conserved post-transcriptional regulators that play essential roles in cellular development and differentiation. Although miRNAs involved in oligodendrocyte lineage cell (OLLC) differentiation have been extensively studied in rodent models, their functions in human oligodendrocyte (OL) development remain poorly understood. To address this, we used a human embryonic stem cell (hESC) reporter system and an optimized differentiation protocol to generate and isolate well-characterized OLLCs at defined developmental stages. Next-generation sequencing-based miRNA profiling identified stage-specific miRNAs associated with OL lineage specification and maturation. In addition to canonical OL-associated miRNAs, we identified several previously uncharacterized oligodendrocyte progenitor cell (OPC)/oligodendrocyte (OL)-enriched miRNAs, including miR-3943, miR-4286, miR-1296-5p, miR-488-3p, miR-675-5p, and miR-128-3p, as potential novel regulators and molecular markers for human OLLC development. Computational target analysis further identified candidate regulatory genes, including ZNF488, DLX1, CSNK2B, and KCNJ1, and predicted their association with AKT, SMAD2/3, estrogen-receptor, and insulin-signaling pathways. Together, these findings provide a comprehensive stage-specific miRNA resource for human OL lineage development and provide insight into potential miRNA-mediated regulatory networks governing human OL development.

1 April 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MBMansoureh Barzegar
Mansoureh Barzegar
YWYuping Wang
Yuping Wang
JYJungmi W. Yun
Jungmi W. Yun
CBChristen J. Boyer
Christen J. Boyer
AMAlireza Minagar
Alireza Minagar
Jonathan Steven AlexanderJonathan Steven Alexander
Jonathan Steven Alexander
Following thrombolytic therapy for stroke, ischemia/reperfusion (I/R) mediated inflammation often disrupts the blood brain barrier (BBB). This can enhance expression of endothelial adhesion markers and perturb normal blood flow regulation. Proposed benefits of stem cell therapy (SCT) in stroke include secretion of protective and trophic factors which limit acute brain I/R injury. We evaluated human placenta mesenchymal stem cells (hPMSC) as potential ameliorative SCT in an acute ischemic stroke model. We hypothesized that potential benefits of hPMSCs, in acute stroke injury, reflect site‐specific suppression of post‐ischemic immune cell adhesion, transvascular leukocyte emigration and preservation of the BBB. This can limit the progression of post –ischemic stroke injury. We found that intraperitoneal (IP) administration of hPMSCs at the time of reperfusion, using the transient middle cerebral artery occlusion (MCAO)/reperfusion model, produced highly significant protection of the ipsilateral hemisphere. We then examined hPMSC support of BBB integrity via mobilization of junctional proteins in human brain endothelial cells (hCMEC‐D3) in conjunction with a biotin/FITC‐avidin permeability assay coupled with western blotting and immunolocalization of junctional proteins. We also assessed the ability of hPMSC to suppress inflammation‐driven hCMEC‐D3 binding of macrophages (RAW264.7) and transmigration of PMNs. In addition, we used collagen gels to study the influence of hPMSC on human brain vascular smooth muscle cells (hBVSMC) tonic contractility. We observed that hPMSC administration significantly (p<0.001) enhanced the barrier integrity of brain endothelial monolayers, at 24h, in an oxygen/glucose deprived/reperfused (OGDR) condition. We found that hCMEC‐D3, which were independently co‐cultured with hPMSCs, expressed significantly higher levels of VE‐cadherin and α‐catenin under OGDR conditions (p<0.001). Additionally, the spatial localization of VE‐cadherin and α‐catenin at hCMEC‐D3 junctions was increased, in the OGDR state, following hPMSC treatment. We also observed that hPMSC treatment significantly (p<0.0001) reduced binding of RAW264.7 to TNF‐α/ LPS activated hCMEC‐D3 monolayers. The expression of VCAM‐1 was increased in TNF‐α/ LPS activated hCMEC‐D3 while this was significantly (p<0.01, P<0.05) decreased by hPMSC treatment. hPMSC also inhibited (p<0.05) PMN transmigration across hCMEC‐D3 monolayers. Lastly, we found that hBVSMC contraction was significantly increased by hPMSC treatment (p=0.0001). This effect was reversed by angiotensin II Type 1 receptor blockade (Losartan, 50μM), angiotensin converting enzyme (Captopril, 50μM), thromboxane A 2 synthesis (Ozagrel, 10μM), and endothelin converting enzyme inhibition (SM19712, 100μM). We conclude that pleiotropic factors associated with hPMSC administration can have a favorable impact on BBB integrity, immune cell interaction, and vasoregulation potentially alleviating the detrimental effects of ischemic stroke. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .